Q-omics provides the consensus-scored BCLAF1P2 profile across patient tissues and cancer cell-line models. BCLAF1P2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCLAF1P2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, BCLAF1P2 RNA expression shows 16,335 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where BCLAF1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCLAF1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCLAF1P2 survival associations across molecular data types. BCLAF1P2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCLAF1P2 RNA expression–survival associations across cancer types. High BCLAF1P2 expression shows unfavorable associations in MESO, KIRP and UVM, but favorable associations in KIRC, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCLAF1P2 RNA expression.
This table summarizes BCLAF1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BCLAF1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCLAF1P2 shows lower tumor expression in KICH and higher tumor expression in HNSC, CHOL, BRCA, COAD and LUAD. The KICH box plot shows higher BCLAF1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.102, t-test p < 0.001).
This table shows molecular features associated with BCLAF1P2 in patient tissues and cancer cell lines. In patient samples, BCLAF1P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
